The European Commission has expanded the scope of Novartis’ Zykadia to include the first line treatment of patients with non-small cell lung cancer (NSCLC) whose tumours are anaplastic lymphoma kinase (ALK)-positive.
Owlstone Medical and Cancer Research UK (CRUK) have begun a clinical trial designed to identify biomarkers of cancer in breath samples. The goal is to find volatile organic compounds (VOCs) that indicate the presence of cancer, enabling physicians to make quick, noninvasive diagnoses.
your submission has already been received.
Please enter a valid Email address！
The most relevant industry news & insight will be sent to you every two weeks.